Collegium Pharmaceutical, Inc.
HealthcareNASDAQ:COLL · NASDAQ Global Select
+$0.30 today
Vol 0.27M · Avg 0.51M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
20.8%
avg -11.8%
ROIC
10.2%
avg -21.9%
ROA
3.8%
avg -12.5%
Analysis
ROE is currently the strongest return metric at 20.8% versus its period average of -11.8%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Vikram Karnani | President, Chief Executive Officer & Director | $1.72M | — | 51 | $209,160.00 | 0.64% |
Colleen Tupper | Executive Vice President & Chief Financial Officer | $1.03M | — | 50 | $153,088.00 | 0.47% |
Scott Dreyer | Executive Vice President & Chief Commercial Officer | $880,739.00 | — | 54 | $75,329.00 | 0.23% |
Thomas Smith FAAFP | Executive Vice President & Chief Medical Officer | $825,694.00 | — | 65 | $108,086.00 | 0.33% |
David Dieter | Executive Vice President, General Counsel & Corporate Secretary | $782,283.00 | — | 62 | $77,071.00 | 0.24% |
Dean J. Patras | Chief People Officer | — | — | — | $61,370.00 | 0.19% |
Ian Karp | Head of Investor Relations | — | — | — | — | — |
Scott Sudduth | EVP & Head of Technical Operations | — | — | — | $75,329.00 | 0.23% |
Jane Gonnerman | Executive Vice President of Strategy & Corporate Development | — | — | — | — | — |
Jessica Cotrone | Senior Vice President of Communications & Corporate Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
19
$10.05M
Net Sentiment
$10.05M
Net selling
Most Active
Dreyer Scott
6 transactions
1–10 of 19
Analysis
Insiders reported 0 buys worth $0.00 and 19 sells worth $10.05M over the last 12 months. That adds up to net selling of $10.05M. Dreyer Scott was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +31.0% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +31.0% (13yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Dynavax Technologies Corporation
DVAX
$1.82B
Pulse Biosciences, Inc.
NASDAQ:PLSE
$1.69B
Innoviva, Inc.
NASDAQ:INVA
$1.68B
Atai Beckley Inc.
NASDAQ:ATAI
$1.44B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
Cronos Group Inc.
NASDAQ:CRON
$1.00B
GoodRx Holdings, Inc.
NASDAQ:GDRX
$918.57M
Pacira BioSciences, Inc.
NASDAQ:PCRX
$904.31M
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
$885.83M
MiMedx Group, Inc.
NASDAQ:MDXG
$536.20M
Who manages COLL?
Collegium Pharmaceutical, Inc. (COLL) lists 10 active executives. The top listed executive is Dean J. Patras, Chief People Officer.
Are COLL insiders buying or selling?
Recent insider activity shows net selling of $42.30M.
Explore More
Continue the stock analysis
Jump to another research area for this company.